Waldschmidt, Johannes M <br/><br/>
Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).  [electronic resource] 

 -  Haematologica  10 2018 
 - e473-e479 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2018.189969  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bortezomib--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Prospective Studies<br/>Survival Rate<br/>Vorinostat--administration & dosage